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OBJECTIVE—The aim of this analysis was to assess the pro-
spective association of serum testosterone and dehydroepiandro-
sterone sulfate (DHEAS) levels with incident metabolic syndrome
(MetS) in men.
RESEARCH DESIGN AND METHODS—Data were obtained
from the Study of Health in Pomerania (SHIP), a population-
based prospective cohort of adults aged 20–79 years. Analyses
were conducted in 1,004 men without baseline MetS deﬁned by
National Cholesterol Education Program Adult Treatment Panel
III guidelines. Testosterone and DHEAS were categorized by
age-speciﬁc quartiles and Poisson regression models with rela-
tive risks (RRs) and 95% CIs were estimated.
RESULTS—After a median follow-up time of 5.0 years, 480 men
(47.8%) developed MetS. Testosterone levels decreased with
increasing number of MetS components. Testosterone in the
lowest quartile predicted MetS (RR 1.38 [95% CI 1.13–1.69]),
particularly among men aged 20–39 years (2.06 [1.29–3.29]), even
after adjustment for age, smoking, alcohol consumption, physical
activity, waist circumference, self-related health, and time of
blood sampling. DHEAS levels were not related to incident MetS
(0.99 [0.83–1.19]).
CONCLUSIONS—Low testosterone but not DHEAS predicts
development of MetS in a population-based cohort of 1,004 men
aged 20–79 years. Especially in young men aged 20–39 years,
results suggest low testosterone as a strong predictor for inci-
dent MetS. Assessment of testosterone in young and middle-age
men may allow early interventions in the general population.
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I
n men, a decline in serum total testosterone and
adrenal androgens like dehydroepiandrosterone sul-
fate (DHEAS) with increasing age is well docu-
mented (1) and has been linked to a variety of
physiological changes including abdominal obesity, insulin
resistance, diabetes, and cardiovascular disease (CVD)
(1,2). The metabolic syndrome (MetS), a concept of clus-
tered metabolic disorders, was established to identify
subjects with increased risk of developing CVD end points.
Previous ﬁndings suggest that low serum testosterone
might be directly associated with MetS, in both cross-
sectional (2,3) and longitudinal studies (4) and consistent
across race and ethnic groups (5). These studies, however,
are somewhat limited by cross-sectional design (2,3,5),
deﬁnition of MetS without adherence to Adult Treatment
Panel III (ATP III) guidelines (6), or study population’s age
structure (40 years of age) (2–4). Low DHEAS levels are
associated with impaired glucose tolerance and insulin
resistance (7). The aim of the present analysis was to
investigate the prospective association of testosterone and
DHEAS levels with incident MetS in a large population-
based sample of 1,004 men aged 20–79 years.
RESEARCH DESIGN AND METHODS
Data from the Study of Health in Pomerania (SHIP) were used (8,9). The target
population was adult German residents of West Pomerania in northeastern
Germany. From 2,117 male baseline participants (response 69%), 1,589 were
repeatedly examined (response 83.6%). Men not followed-up (n  528) or with
baseline MetS (n  450) were excluded. Another 77 men who used opiates
(anatomic-therapeutical-chemical [ATC] code N02AA, A07DA02, R05DA, and
R05FA0; n  11), glucocorticoids (ATC code R03BA, n  31; H02AB, n  28),
sexual hormones (ATC code G03; n  2), testosterone 5 reductase inhibitors
(ATC code G04CB; n  4), or sexual hormone antagonists (ATC code L02B;
n  1) were also excluded. Among the remaining 1,062 men, 1 man with
testosterone 55.5 nmol/l (1,599.5 ng/dl), 9 men with testosterone 0.69
nmol/l (19.9 ng/dl), and a further 48 men with missing data on testosterone,
DHEAS, or confounders were excluded. Thus, the ﬁnal study population
comprised 1,004 men.
Sociodemographic and behavioral characteristics were assessed by com-
puter-assisted personal interviews. Mean daily alcohol consumption was
calculated using beverage-speciﬁc pure ethanol volume proportions (10).
Riskful alcohol consumption was classiﬁed as 30 g alcohol/day. Smoking
habits were assessed by dividing men into categories of current, former, and
never smokers. Men who participated in physical training during summer or
winter for at least 1 h/week were classiﬁed as being physically active.
Self-related health was assessed by the single-item question: “Over the last 12
months, would you say your health has been very good, good, fair, poor, or
very poor?” The deﬁnition of diabetes was based on self-reported physicians
diagnosis or self-reported use of antidiabetic medication (ATC code A10).
Waist circumference was measured to the nearest 0.1 cm using an inelastic
tape midway between the lower rib margin and the iliac crest in the horizontal
plane with the subject standing comfortably with weight distributed evenly on
both feet. Height was measured to the nearest 1 cm using a digital ultrasound
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DIABETES, VOL. 58, SEPTEMBER 2009 2027instrument, and weight was measured to the nearest 0.1 kg in light clothing
and without shoes using standard digital scales (Soehnle-Waagen, Nassau,
Germany). BMI was calculated as weight in kilograms divided by the square of
height in meters. After a 5-min rest period, systolic and diastolic blood
pressure was measured three times in the right arm of seated subjects using
a digital blood pressure monitor (HEM-705CP; Omron, Tokyo, Japan) with
each reading being followed by a further rest period of 3 min. The last two
readings were averaged to give the mean diastolic and systolic blood pressure.
Hypertension was deﬁned as elevated mean systolic (130 mmHg) and
diastolic (85 mmHg) blood pressure or use of antihypertensive medication
(ATC code C02). MetS was deﬁned by any three or more of the ﬁve
components proposed by ATP III (6) and recently updated with minor
modiﬁcations by the American Heart Association (AHA) and the National
Heart, Lung, and Blood Institute (NHLBI) (11) and were modiﬁed for the use
of nonfasting blood samples (12): 1) abdominal obesity, waist circumference
94 cm in men; 2) elevated triglycerides, 2.0 mmol/l or lipid medication
(ATC code C10ab); 3) low HDL cholesterol, 1.03 mmol/l in men; 4) high
blood pressure, 130/85 mmHg or antihypertensive medication (ATC code C02);
5) high blood glucose, 8.0 mmol/or diabetes medication (ATC code A10).
Nonfasting blood samples were drawn from the cubital vein in the supine
position. The samples were taken between 7:00 A.M. and 04:00 P.M., and serum
aliquots were prepared for immediate analysis and for storage at 80°C for
further analysis. Testosterone and DHEAS levels were measured from frozen
serum aliquots using competitive chemiluminescent enzyme immunoassays
on an Immulite 2500 analyzer (Siemens Healthcare Medical Diagnostics, Bad
Nauheim, Germany) (13). Baseline total and HDL cholesterol were measured
photometrically (Hitachi 704; Roche, Mannheim, Germany). Follow-up HDL
cholesterol was quantiﬁed by lipid electrophoresis (HELENA SAS-3 system;
Helena 7 BioSciences Europe, Tyne & Wear, U.K.). To ensure comparability,
we applied a previously published conversion factor (14) with virtually no
differences in the estimates (data not shown). Dyslipidemia was deﬁned by
ratio of total to HDL cholesterol 5.0 mmol/l (15). Triglycerides and glucose
were determined enzymatically using reagents from Roche Diagnostics (Hita-
chi 717; Roche Diagnostics, Mannheim, Germany).
Statistical Analysis. Descriptive statistics, proportions for categorical vari-
ables, and means  SD or medians (interquartile range) for continuous
variables were used to describe the study population. Univariate statistics
were performed with 
2 testing for categorical variables and Wilcoxon test for
continuous variables. Hormone levels were assessed by age-speciﬁc (decades)
quartiles. Effects were estimated using generalized linear models with Poisson
distribution, log link function, and robust error variances presented in relative
risks (RRs) and 95% CIs. Adjustments included age, smoking habits, alcohol
consumption, physical activity, waist circumference, self-related health, and
blood sampling time. The P value for trend was calculated to test for linearity
of RRs. Receiver operating characteristic analysis was evaluated if the
measurement of testosterone added signiﬁcantly to the prediction of MetS by
standard risk factors. All P values were two tailed, and P  0.05 was
considered statistically signiﬁcant. All analyses were performed with Stata 9.0
(Stata, College Station, TX).
RESULTS
After a median follow-up time of 5.0 years (range 4.4–8.3),
480 men (47.8%) developed MetS. The analytical sample
appeared to be healthier than the full sample, whereas
men with incident MetS were signiﬁcantly older, exposed
to lower testosterone and DHEAS levels, scored worse for
self-related health, were physically less active showed
higher body fat accumulation, and exposed signiﬁcant
differences in all MetS components than men without
incident MetS (Table 1). We detected an overall trend of
increasing risk of incident MetS with decreasing levels of
both testosterone and DHEAS in unadjusted analyses
(Table 2). The risk of incident MetS was highest for men
with baseline testosterone and DHEAS levels in the lowest
quartile (unadjusted RR 1.52 [95% CI 1.25–1.85]) and 1.38
[1.16–1.65], respectively) than the highest quartile. P for
trend statistics revealed that RRs were also linearly ele-
vated (P for trend  0.001). Stratifying analyses by 20-year
TABLE 1
Baseline characteristics of men by full and analytical sample
Full sample Analytical sample
Without MetS
at follow-up
Incident MetS
at follow-up
n 2,117 1,004 524 480
Age (years) 51.3  16.6 48.7  15.9* 45.6  15.7 51.9  15.5*
Total testosterone (nmol/l) 15.9 (12.7–20.1) 16.6 (13.4–20.6)* 17.7 (14.4–21.5) 15.5 (12.6–19.1)*
DHEAS (g/dl) 1.63 (0.96–2.56) 1.74 (1.09–2.69)* 1.98 (1.25–2.83) 1.58 (0.94–2.52)*
Daily alcohol consumption (g/day) 11.9 (1.5–28.2) 13.6 (2.5–28.9) 16.5 (2.7–30.3) 10.0 (0.0–27.2)*
Riskful alcohol consumption 23.0 23.9 25.2 22.5
Self-related health
Very good 2.1 2.3* 2.5 2.1*
Good 15.4 19.1* 21.4 16.7*
Fair 64.0 64.6* 66.4 62.7*
Poor/very poor 18.4 13.9* 9.7 18.5*
Smoking
never smoker 21.0 24.2* 26.5 21.7
ex-smoker 45.3 42.2* 39.3 45.4
current smoker 33.7 33.6* 34.2 32.9
Physical activity 41.0 46.7* 50.4 42.7*
BMI (kg/m²) 27.6  4.0 26.4  3.3* 25.5  3.2 27.4  3.0*
Waist circumference (cm) 102.0 (97.6–107.2) 100.3 (96.4–104.3)* 98.8 (94.8–103.3) 101.9 (98.3–105.7)*
Systolic blood pressure (mmHg) 143.6  19.5 139.2  17.9* 134.6  16.3 141.2  17.8*
Diastolic blood pressure (mmHg) 86.3  11.3 85.0  10.9* 83.0  10.8 86.8  10.4*
Hypertension 62.4 59.8* 56.1 63.8
Glucose (mmol/l) 5.9  1.9 5.4  1.3* 5.2  0.63 5.6  1.7*
Triglycerides (mmol/l) 2.13  1.61 1.77  1.42* 1.41  0.83 2.12  1.80
HDL cholesterol (mmol/l) 1.30  0.37 1.38  0.34* 1.49  0.35 1.28  0.28
Diabetes 8.8 7.2* 6.7 7.7
Dyslipidemia 62.0 56.5* 33.4 81.7
Data are percentages, means  SD, or medians (interquartile range). To convert the values of serum testosterone to ng/dl multiply by 28.82.
To convert the values of serum DHEAS to mol/l multiply by 0.027. *P  0.05 using 
2 test (nominal data) and Wilcoxon test (continuous
data) for bivariate comparisons between analytical sample and full sample as well as between subjects with and without metabolic syndrome
at follow-up, respectively.
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2028 DIABETES, VOL. 58, SEPTEMBER 2009age-groups revealed that in particular, young (20–39
years) (2.50 [1.58–3.96]) and middle-aged (40–59 years)
(1.41 [1.06–1.89]) men were exposed to elevated risk of
incident MetS from low baseline testosterone. Further
adjustment for age, smoking, alcohol consumption, phys-
ical activity, waist circumference, self-related health, and
time of blood sampling conﬁrmed the prospective associ-
ation between low testosterone and incident MetS,
whereas the association between low DHEAS and MetS
was no longer consistent (Table 2). Adjusted RRs for
lowest compared with highest quartile of testosterone by
20-year age-groups was 2.06 (95% CI 1.29–3.29) for men
aged 20–39 years, 1.34 (1.00–1.81) for men aged 40–59
years, and 1.00 (0.75–1.37) for men aged 60–79 years. In
receiver operating characteristic analysis, the inclusion of
continuous testosterone in the multivariable basic model
improved prediction of incident MetS signiﬁcantly (P 
0.001). Furthermore, a distinct trend of decreasing testos-
terone with increasing number of incident MetS compo-
nents was observed in all three age-groups (Fig. 1). With
regard to DHEAS, Fig. 2 displayed an inverted “U” shape
over increasing number of MetS components.
DISCUSSION
Our results from a population-based sample of 1,004 men
aged 20–79 years revealed an inverse association between
baseline testosterone and the development of MetS inde-
pendent of important confounding factors. Especially in
young men aged 20–39 years, low testosterone was a
strong predictor for incident MetS. Baseline DHEAS did
not show an independent prospective association with
incident MetS. The association of low testosterone not
only with components of MetS but also with MetS itself
was previously reported from different cross-sectional
studies in varying populations (2,3,5) as well as from
longitudinal studies (4). Our ﬁnding of an independent
prospective association of testosterone with MetS in
young men has not been reported previously. Most re-
markably, the association appeared to be stronger in
young and middle-age men than in the elderly.
Although the temporal sequence of low testosterone
preceding the development of MetS suggests a causal
relationship between the two phenomena, we cannot
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FIG. 1. Means with 95% CI in the analytical sample (n  1,004) for total
testosterone levels according to zero, one, two, three, four, or more
components of MetS at baseline by 20-year age-groups. To convert the
values of serum testosterone to ng/dl multiply by 28.82.
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early consequence of mechanisms ﬁnally leading to MetS.
There is evidence for both views because, on the one hand,
weight loss in obese men and in men with MetS increased
free and total testosterone as well as sex hormone–
binding globulin levels (16) and, on the other hand, inter-
ventional studies with testosterone in men with low serum
levels decreased fat mass, total cholesterol, and LDL
cholesterol (17,18). Thus, the possibility exists that there
is a vicious cycle between low testosterone and metabolic
alterations leading to MetS and consequently contributing
to more severe complications such as type 2 diabetes and
CVD. Given reports of greatly increased MetS prevalence
in hypogonadism from Klinefelter’s syndrome with little
effect of testosterone treatment on body composition (19)
and higher cardiovascular risk among men undergoing
long-term androgen-deprivation therapy (20), we recom-
mend interventional studies of exogenous testosterone
supplementation in men with MetS to further delineate the
causal relationship of testosterone and MetS.
The present ﬁndings suggest that DHEAS is not associ-
ated with MetS. Although previous observational studies
were able to detect an association of DHEAS and ischemic
heart disease (21), the clinical signiﬁcance of DHEAS in
CVD remains uncertain (22). So, the possibilities to ex-
plain why in our study testosterone is a predictor of MetS
whereas DHEAS is not are broad, ranging from differences
in study population’s age structure, time of blood sam-
pling, or laboratory methodology. However, data from
prospective randomized trials are needed to illuminate the
basic physiological role of DHEAS in CVD and to clarify
whether DHEAS supplementation has any cardiovascular
beneﬁt.
Limitations arise from the lack of measured free testos-
terone, sex hormone–binding globulin, or albumin for
calculation of bioavailable testosterone as well as from
single measurement of testosterone. Due to logistical
impossibilities, we used nonfasting blood samples for the
deﬁnition of MetS. However, because differences between
fasting and nonfasting participants are reported to be
negligible (23), fasting status is unlikely to cause associa-
tions. In summary, our results suggest that testosterone
may serve as an early indicator for future metabolic risk.
Therefore, further studies should examine whether testos-
terone supplementation protects against the development
of MetS, especially in younger and middle-aged men.
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